CO2017009061A2 - Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes - Google Patents
Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenesInfo
- Publication number
- CO2017009061A2 CO2017009061A2 CONC2017/0009061A CO2017009061A CO2017009061A2 CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2 CO 2017009061 A CO2017009061 A CO 2017009061A CO 2017009061 A2 CO2017009061 A2 CO 2017009061A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyogenes
- variant polypeptides
- degradation enzyme
- igg
- immunoglobulin
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 108060003951 Immunoglobulin Proteins 0.000 title 1
- 241000193996 Streptococcus pyogenes Species 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000018358 immunoglobulin Human genes 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 102000005927 Cysteine Proteases Human genes 0.000 abstract 1
- 108010005843 Cysteine Proteases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
- C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502306A GB201502306D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| PCT/EP2016/053052 WO2016128558A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017009061A2 true CO2017009061A2 (es) | 2018-01-16 |
Family
ID=52781456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0009061A CO2017009061A2 (es) | 2015-02-12 | 2017-09-04 | Polipéptidos variantes de la enzima de degradación de inmunoglobulina g del s. pyogenes |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US10696959B2 (enExample) |
| EP (2) | EP3256580B1 (enExample) |
| JP (1) | JP6961486B2 (enExample) |
| KR (1) | KR102524613B1 (enExample) |
| CN (2) | CN114231512B (enExample) |
| AU (2) | AU2016217800B2 (enExample) |
| BR (1) | BR112017017284A2 (enExample) |
| CA (1) | CA2976003A1 (enExample) |
| CL (1) | CL2017002065A1 (enExample) |
| CO (1) | CO2017009061A2 (enExample) |
| DK (1) | DK3256580T3 (enExample) |
| EA (1) | EA035130B1 (enExample) |
| ES (1) | ES2927234T3 (enExample) |
| GB (1) | GB201502306D0 (enExample) |
| IL (1) | IL253938B (enExample) |
| LT (1) | LT3256580T (enExample) |
| MX (1) | MX390806B (enExample) |
| MY (1) | MY188696A (enExample) |
| PL (1) | PL3256580T3 (enExample) |
| PT (1) | PT3256580T (enExample) |
| SG (1) | SG11201706346QA (enExample) |
| WO (1) | WO2016128558A1 (enExample) |
| ZA (1) | ZA201705113B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CA3095179A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Antibody-evading virus vectors |
| BR112020020266A2 (pt) | 2018-04-03 | 2021-01-19 | Stridebio, Inc. | Vetores de vírus com evasão de anticorpos |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| CN113727992A (zh) | 2019-03-21 | 2021-11-30 | 斯特里迪比奥公司 | 重组腺相关病毒载体 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| MX2022004353A (es) | 2019-10-17 | 2022-07-19 | Casete de transferencia de aav. | |
| CN114787180A (zh) | 2019-10-17 | 2022-07-22 | 斯特里迪比奥公司 | 用于治疗c型尼曼-匹克病的腺相关病毒载体 |
| IL309560B2 (en) | 2019-12-06 | 2025-05-01 | Regeneron Pharma | Anti-VEGF protein preparations and methods for their production |
| AU2021218703A1 (en) | 2020-02-14 | 2022-07-28 | Ultragenyx Pharmaceutical Inc. | Gene therapy for treating CDKL5 deficiency disorder |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| GB202003129D0 (en) * | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| US20230277633A1 (en) | 2020-06-05 | 2023-09-07 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical composition of enzymes and viruses and application thereof |
| WO2021254479A1 (zh) * | 2020-06-18 | 2021-12-23 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| JP2023542614A (ja) | 2020-08-19 | 2023-10-11 | サレプタ セラピューティクス， インコーポレイテッド | レット症候群の治療のためのアデノ随伴ウイルスベクター |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| JP2024515626A (ja) | 2021-04-16 | 2024-04-10 | アスクレピオス バイオファーマシューティカル， インコーポレイテッド | 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| JP2024531138A (ja) | 2021-08-11 | 2024-08-29 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 筋ジストロフィーを処置するための組成物および方法 |
| EP4433587A2 (en) | 2021-11-15 | 2024-09-25 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| JP2024546152A (ja) | 2021-12-16 | 2024-12-17 | 上海宝済薬業股▲ふん▼有限公司 | 免疫グロブリン分解酵素による切断に対抗するＦｃ変異体 |
| WO2023116817A1 (zh) | 2021-12-22 | 2023-06-29 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体的用途 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115873833B (zh) * | 2022-11-08 | 2024-08-16 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| AU2023383441A1 (en) | 2022-11-18 | 2025-06-05 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| WO2024148276A1 (en) | 2023-01-06 | 2024-07-11 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| EP4784739A1 (en) * | 2023-09-27 | 2026-08-05 | Adaxion Therapeutics, Inc. | Polypeptides having human igg cleavage activity |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| GB202413764D0 (en) | 2024-09-18 | 2024-10-30 | Genovis Ab | Immunoglobulin proteases and their uses |
| WO2026072947A1 (en) * | 2024-09-26 | 2026-04-02 | Cyrus Biotechnology, Inc. | Ides variant proteins and methods of using the same |
| GB202414654D0 (en) | 2024-10-04 | 2024-11-20 | Hansa Biopharma AB | Regimen for vector-based therapies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| EP1343895B1 (en) | 2000-12-21 | 2008-06-18 | ID Biomedical Corporation | Streptococcus pyogenes antigens and corresponding dna fragments |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| EP1576964A4 (en) * | 2002-11-29 | 2008-06-11 | Morinaga Milk Industry Co Ltd | PROTEASE INHIBITOR |
| CN1756843B (zh) * | 2003-03-04 | 2012-03-21 | 英特塞尔股份公司 | 化脓链球菌抗原 |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| CN105770871A (zh) * | 2005-06-09 | 2016-07-20 | 汉莎医药有限公司 | IdeS蛋白酶(来自于酿脓链球菌)在自身免疫性疾病和移植排斥的治疗中的用途 |
| US7544577B2 (en) | 2005-08-26 | 2009-06-09 | International Business Machines Corporation | Mobility enhancement in SiGe heterojunction bipolar transistors |
| CN102584989B (zh) * | 2007-09-14 | 2015-05-13 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物及纯化与检测IgG的方法和试剂盒 |
| AU2008336295B2 (en) | 2007-12-13 | 2013-07-11 | Intervacc Ab | Improved immunizing composition |
| WO2009080278A1 (en) | 2007-12-21 | 2009-07-02 | F. Hoffmann-La Roche Ag | Stability testing of antibodies |
| WO2010089126A2 (en) | 2009-02-09 | 2010-08-12 | Roche Glycart Ag | Immunoglobulin glycosylation pattern analysis |
| EP3135684B1 (en) | 2010-05-26 | 2023-06-28 | Intervacc AB | Vaccine against streptococcal infections based on recombinant fusion proteins |
| GB201115841D0 (en) * | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| CN103214549B (zh) * | 2013-01-15 | 2015-08-05 | 珠海市丽珠单抗生物技术有限公司 | 一种还原免疫球蛋白的方法及其试剂盒 |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
-
2015
- 2015-02-12 GB GB201502306A patent/GB201502306D0/en not_active Ceased
-
2016
- 2016-02-12 MX MX2017010390A patent/MX390806B/es unknown
- 2016-02-12 CN CN202111557859.9A patent/CN114231512B/zh active Active
- 2016-02-12 CN CN201680021601.8A patent/CN107532156A/zh active Pending
- 2016-02-12 CA CA2976003A patent/CA2976003A1/en active Pending
- 2016-02-12 WO PCT/EP2016/053052 patent/WO2016128558A1/en not_active Ceased
- 2016-02-12 PT PT167076538T patent/PT3256580T/pt unknown
- 2016-02-12 SG SG11201706346QA patent/SG11201706346QA/en unknown
- 2016-02-12 EA EA201791773A patent/EA035130B1/ru not_active IP Right Cessation
- 2016-02-12 US US15/550,309 patent/US10696959B2/en active Active
- 2016-02-12 BR BR112017017284A patent/BR112017017284A2/pt not_active Application Discontinuation
- 2016-02-12 EP EP16707653.8A patent/EP3256580B1/en active Active
- 2016-02-12 LT LTEPPCT/EP2016/053052T patent/LT3256580T/lt unknown
- 2016-02-12 PL PL16707653.8T patent/PL3256580T3/pl unknown
- 2016-02-12 AU AU2016217800A patent/AU2016217800B2/en active Active
- 2016-02-12 EP EP22174919.5A patent/EP4108768A1/en active Pending
- 2016-02-12 MY MYPI2017001124A patent/MY188696A/en unknown
- 2016-02-12 KR KR1020177025560A patent/KR102524613B1/ko active Active
- 2016-02-12 DK DK16707653.8T patent/DK3256580T3/da active
- 2016-02-12 ES ES16707653T patent/ES2927234T3/es active Active
- 2016-02-12 JP JP2017542896A patent/JP6961486B2/ja active Active
-
2017
- 2017-07-27 ZA ZA2017/05113A patent/ZA201705113B/en unknown
- 2017-08-10 IL IL253938A patent/IL253938B/en active IP Right Grant
- 2017-08-11 CL CL2017002065A patent/CL2017002065A1/es unknown
- 2017-09-04 CO CONC2017/0009061A patent/CO2017009061A2/es unknown
-
2020
- 2020-05-20 US US16/879,324 patent/US11214784B2/en active Active
-
2021
- 2021-11-11 AU AU2021266293A patent/AU2021266293B2/en active Active
- 2021-12-14 US US17/644,315 patent/US11667905B2/en active Active
-
2023
- 2023-05-16 US US18/318,455 patent/US12359183B2/en active Active
-
2025
- 2025-06-09 US US19/232,657 patent/US20250304937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017009060A2 (es) | Polipéptido hibrido de la enzima de degradación inmunoglobulina g del s. pyogenes y enzima de degradación de inmunoglobulina g del streptococcus equi ssp. zooepidemicus | |
| MX390806B (es) | Proteasa de cisteina. | |
| EA201792583A1 (ru) | Способы и композиции для ингибирования взаимодействия менина с белками mll | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| MX391159B (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
| UY36905A (es) | Anticuerpos neutralizantes de poliomavirus | |
| MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2019008359A (es) | Cadena j modificada. | |
| MX2016009625A (es) | Proteinas quimericas tipo fosfatasa alcalina. | |
| MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX2016013803A (es) | Manufactura de neurotoxinas del clostridium botulinum recombinantes. | |
| ECSP17003946A (es) | Anticuerpos antagonistas del interferón alfa y omega | |
| CR20160561A (es) | Variantes del anticuerpo anti-factor d y sus usos | |
| MX2017002469A (es) | Composiciones de matrices extracelulares. | |
| MX373805B (es) | Agonistas de receptor fgf21 y usos del mismo. | |
| CL2018002898A1 (es) | Nuevos anticuerpos anti-sirpa y sus aplicaciones terapéuticas. | |
| MX2017002796A (es) | Tasimelteon para tratar el sindrome de smith-magenis. | |
| BR112017024908A2 (pt) | usos terapêuticos da 4-cloroquinurenina | |
| BR112016019389A8 (pt) | Vacina, e, peptídeo | |
| CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. |